Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the…
Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on the heels of a positive Phase III study in…
Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs),…
DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of DED, and the condition may eventually lead to damage to…